Clinical Trial

Detection of Minimal Residual Disease Post-prostatectomy

Name: Detection of Minimal Residual Disease Post-prostatectomy — clinical trial record (NCT07334275)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MiRaDE

Recruiting

View on ClinicalTrials.gov →

Summary

The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.

Trial Details

NCT Number	NCT07334275
Lead Sponsor	Radboud University Medical Center Collaborators: Catharina Ziekenhuis Eindhoven, Canisius-Wilhelmina Hospital, Maxima Medical Center
Conditions	Prostate Cancer
Enrollment	50 participants
Start Date	2025-09-16
Primary Completion	2027-07 (estimated)
Study Completion	2028-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-12